Home ETF List About

ETF Holdings Breakdown of MLYS

Stock NameMineralys Therapeutics, Inc. Common Stock
TickerMLYS(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS6031701013

MLYS institutional holdings

The following institutional investment holdings of MLYS have been identified

Date ETF ISIN/Name Num Shares Book value
2025-10-17 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 3,784USD 164,831
2025-10-17 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 41,649USD 1,814,230
2025-10-17 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 41,649USD 1,814,230
2025-10-17 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 33,971USD 1,479,777
Total =121,053 USD 5,273,068
Book value of shares is calculated on the adjusted close price of each day (row).

News associated with MLYS

Mineralys Therapeutics (NASDAQ:MLYS) Sees Strong Trading Volume on Analyst Upgrade
Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) shares saw unusually-high trading volume on Thursday after Wells Fargo & Company raised their price target on the stock from $26.00 to $50.00. Wells Fargo & Company currently has an overweight rating on the stock. Approximately 792,595 shares changed hands during trading, a decline of 26% from […] - 2025-09-12 02:42:55
The Goldman Sachs Group Forecasts Strong Price Appreciation for Mineralys Therapeutics (NASDAQ:MLYS) Stock
Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) had its target price raised by equities researchers at The Goldman Sachs Group from $32.00 to $52.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. The Goldman Sachs Group’s target price points to a potential upside of […] - 2025-09-11 03:13:15
Mineralys Therapeutics Reaches Analyst Target Price
In recent trading, shares of Mineralys Therapeutics Inc (Symbol: MLYS) have crossed above the average analyst 12-month target price of $38.25, changing hands for $38.50/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgr - 2025-09-10 07:47:17
Mineralys Therapeutics (NASDAQ:MLYS) Receives “Buy” Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of Mineralys Therapeutics (NASDAQ:MLYS – Free Report) in a research note released on Monday,Benzinga reports. The brokerage currently has a $42.00 target price on the stock. A number of other research firms have also weighed in on MLYS. Jefferies Financial Group raised their price target on shares […] - 2025-09-09 03:10:46
Mineralys Therapeutics (NASDAQ:MLYS) Price Target Raised to $26.00 at Jefferies Financial Group
Mineralys Therapeutics (NASDAQ:MLYS – Free Report) had its price objective hoisted by Jefferies Financial Group from $15.00 to $26.00 in a research report released on Wednesday morning,Benzinga reports. Jefferies Financial Group currently has a hold rating on the stock. A number of other research analysts have also recently commented on MLYS. Guggenheim set a $48.00 […] - 2025-09-04 05:16:51
Alps Advisors Inc. Sells 5,584 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)
Alps Advisors Inc. cut its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Free Report) by 13.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 34,664 shares of the company’s stock after selling 5,584 shares during the quarter. Alps […] - 2025-07-15 06:25:59
Head to Head Analysis: Mineralys Therapeutics (NASDAQ:MLYS) & Basilea Pharmaceutica (OTCMKTS:BPMUF)
Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) and Basilea Pharmaceutica (OTCMKTS:BPMUF – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership. Profitability This table compares Mineralys Therapeutics and […] - 2025-07-08 05:06:49
Bank of America Corp DE Purchases 11,549 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)
Bank of America Corp DE raised its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Free Report) by 12.0% during the fourth quarter, Holdings Channel reports. The fund owned 107,703 shares of the company’s stock after buying an additional 11,549 shares during the period. Bank of America Corp DE’s holdings in Mineralys Therapeutics were worth $1,326,000 […] - 2025-06-06 04:34:57
10,405 Shares in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Acquired by ProShare Advisors LLC
ProShare Advisors LLC bought a new position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 10,405 shares of the company’s stock, valued at approximately $128,000. A number of other […] - 2025-06-03 04:50:50
Mineralys Therapeutics (NASDAQ:MLYS) Sees Strong Trading Volume on Analyst Upgrade
Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) saw strong trading volume on Wednesday after HC Wainwright raised their price target on the stock from $30.00 to $42.00. HC Wainwright currently has a buy rating on the stock. 303,503 shares were traded during trading, a decline of 17% from the previous session’s volume of 367,553 […] - 2025-04-04 02:17:07
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Bought by AlphaQuest LLC
AlphaQuest LLC boosted its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Free Report) by 2,637.8% in the fourth quarter, HoldingsChannel.com reports. The fund owned 15,222 shares of the company’s stock after purchasing an additional 14,666 shares during the period. AlphaQuest LLC’s holdings in Mineralys Therapeutics were worth $187,000 at the end of the […] - 2025-03-17 06:03:05
23,192 Shares in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Acquired by Proficio Capital Partners LLC
Proficio Capital Partners LLC purchased a new position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 23,192 shares of the company’s stock, valued at approximately $285,000. Other institutional investors and hedge funds have also bought and […] - 2025-03-12 05:14:51
HC Wainwright Reiterates Buy Rating for Mineralys Therapeutics (NASDAQ:MLYS)
HC Wainwright restated their buy rating on shares of Mineralys Therapeutics (NASDAQ:MLYS – Free Report) in a report issued on Monday morning,Benzinga reports. The firm currently has a $30.00 price objective on the stock. MLYS has been the subject of several other research reports. Guggenheim restated a “buy” rating on shares of Mineralys Therapeutics in […] - 2025-03-11 04:40:47

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.